Request Demo

Last update 29 Jul 2026

Ergocalciferol

Last update 29 Jul 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

(3β,5Z,7E,22E)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol, (5Z,7E,22E)-(3S)-9,10-seco-5,7,10(19),22-ergostatetraen-3-ol, (5Z,7E,22E)-(3S)-9,10-secoergosta-5,7,10(19),22-tetraen-3-ol

+ [17]

Target

VDR

Action

agonists

Mechanism

VDR agonists(Vitamin D receptor agonists)

Therapeutic Areas

Congenital DisordersEndocrinology and Metabolic DiseaseSkin and Musculoskeletal Diseases+ [1]

Active Indication

HypocalcemiaHypophosphatemia, FamilialOsteomalacia+ [3]

Inactive Indication-

Originator Organization

SS Pharmaceuticals

Active Organization

Sunflower Pharmaceutical Group Co., Ltd.Esjay Pharma LLC

Inactive Organization-

License Organization

Jiangxi Tianzhihai Pharmaceutical Co., Ltd.

Guangxi Wuzhou Zhongheng Group Co., Ltd.

Chongqing Lummy Pharmaceutical Co., Ltd.

Drug Highest PhaseApproved

First Approval Date

United States (11 Jan 1941),

HypoparathyroidismHypophosphatemiaRickets

Regulation-

Structure/Sequence

Molecular FormulaC28H44O

InChIKeyMECHNRXZTMCUDQ-RKHKHRCZSA-N

CAS Registry50-14-6

120

Clinical Trials associated with Ergocalciferol

NCT07670611

/ RecruitingPhase 4IIT

Accelerated Correction of Vitamin D Deficiency in Cholestatic Children: a Comparative Trial of Vitamin D2 Monotherapy vs Combination Therapy With Calcitriol

The goal of this clinical trial is to learn whether adding calcitriol to vitamin D2 can improve vitamin D deficiency in children with cholestasis and chronic liver disease. Cholestasis is a condition in which bile flow is reduced, which can make it difficult for the body to absorb and process vitamin D. The study will also learn about the safety of using vitamin D2 together with calcitriol.
The main questions it aims to answer are:
* Does vitamin D2 plus calcitriol increase blood 25-hydroxyvitamin D (25-OHD) levels more than vitamin D2 alone after 3 months of treatment?
* Does vitamin D2 plus calcitriol help more children reach an adequate vitamin D level by 3 and 6 months?
* What medical problems, especially high calcium or high phosphorus levels, occur during treatment?
Researchers will compare children who receive vitamin D2 alone with children who receive vitamin D2 plus calcitriol to see which treatment improves vitamin D levels more effectively and safely.
Participants will:
* Take vitamin D2 alone or vitamin D2 plus calcitriol as assigned by randomization
* Visit the clinic for study assessments at the start of the study, at 3 months, and at 6 months
* Have blood tests to measure vitamin D levels, calcium, phosphorus, parathyroid hormone, liver function, and other safety markers
* Have their treatment reviewed at 3 months; participants whose vitamin D level remains low may have their treatment adjusted according to the study plan
* Bring back medication packages so researchers can check how regularly the study medicines were taken

Start Date28 Apr 2026

Sponsor / Collaborator-

NCT07366450

/ Not yet recruitingNot ApplicableIIT

Safety and Efficacy of High-Intensity Loading Dose Versus Standard Weekly Dosing of Ergocalciferol (Vitamin D2) for Vitamin D Normalization in Patients With Newly Diagnosed Aggressive Non-Hodgkin Lymphoma: A Randomized, Open-Label, Controlled Trial

The goal of this clinical trial is to evaluate whether a high-intensity loading dose of ergocalciferol (vitamin D2) can normalize blood vitamin D levels more rapidly and safely than standard weekly dosing in patients with newly diagnosed aggressive non-Hodgkin lymphoma. The study will also assess the safety of both dosing strategies.
The main questions it aims to answer are:
* Does a high-intensity loading dose of ergocalciferol lead to faster normalization of serum 25-hydroxyvitamin D levels compared with standard weekly dosing?
* Are there differences in safety and adverse events between the two dosing strategies?
Researchers will compare a high-intensity loading dose regimen of ergocalciferol with a standard weekly dosing regimen to determine differences in vitamin D normalization and safety outcomes.
Participants will:
* Be randomly assigned to receive either a high-intensity loading dose or a standard weekly dose of ergocalciferol (vitamin D2)
* Receive standard first-line immunochemotherapy for aggressive non-Hodgkin lymphoma
* Have blood tests to monitor vitamin D levels, calcium, phosphate, and safety parameters at scheduled visits
* Be followed for treatment response, survival outcomes, and adverse events during and after therapy

Start Date01 Feb 2026

Sponsor / Collaborator

Phramongkutklao College of Medicine

ChiCTR2600121935

/ RecruitingNot ApplicableIIT

A Study on the Efficacy of Vitamin D Supplementation in Adolescents with Unipolar Depression

Start Date01 Sep 2025

Sponsor / Collaborator

Nanfang Hospital

100 Clinical Results associated with Ergocalciferol

100 Translational Medicine associated with Ergocalciferol

100 Patents (Medical) associated with Ergocalciferol

3,013

Literatures (Medical) associated with Ergocalciferol

01 Jul 2026·FOOD CHEMISTRY

Green and sustainable dual-pathway strategies for high-efficiency photoconversion of ergosterol to vitamin D₂ from agaricus bisporus

Article

Author: Yu, Jiahao ; Shen, Mofei ; Feng, Simin ; Tang, Yan ; Lin, Yang ; Shao, Ping

The conversion of ergosterol to vitamin D₂ (VD₂) in Agaricus bisporus is still limited by low efficiency. This study integrates a particle size-regulated powder photoconversion pathway and natural deep eutectic solvent (NADES) integrated extraction-photoconversion pathway to achieve a high VD₂ yield. In the powder pathway, combining UV-B irradiation with a median particle size of 130-140 μm maximized VD₂ yield, reaching 2.59% by balancing optical penetration depth, light shielding, and the resulting porous cellular structure. In the extract pathway, the menthol-based NADES system was developed to achieve simultaneous high-efficiency ergosterol extraction (85.41% extraction efficiency) and stabilization, as well as ergosterol photoconversion to VD₂ (4.08% yield), attributed to enhanced cell permeability and hydrogen bonding interactions. The NADES system also enhanced the storage stability of ergosterol and VD₂ by 24.79% and 20.53%, respectively, compared to the ethanol during storage. This work provides green and tunable dual-pathway strategies for developing high-value VD₂-enriched products.

01 Jul 2026·JOURNAL OF MOLECULAR GRAPHICS & MODELLING

In silico screening and molecular dynamics simulations of Epicatechin as an inhibitor of EBV LMP1

Article

Author: Salam, Dayang-Sharyati D A

Epstein-Barr Virus (EBV) Latent Membrane Protein 1 (LMP1) is a critical oncoprotein and a high-value target for therapeutics against EBV-associated malignancies. This study employed an integrated in silico approach-combining virtual screening, molecular docking, 250 ns all-atom Molecular Dynamics (MD) simulations in a lipid bilayer, and ADMET prediction-to identify potent LMP1 inhibitors among nutraceutical compounds. Virtual screening of over 700 compounds led to the selection of five top ligands for MD analysis against the full-length LMP1 protein. MD simulations revealed a crucial divergence from static docking, with Epicatechin and Vitamin D2 emerging as the potential stable binders, targeting the protein's C-Terminal Activation Region (CTAR) and Transmembrane Domain (TMD). Epicatechin was predicted as the most thermodynamically favourable binder, exhibiting the strongest total binding free energy (ΔTOTAL = -29.07 ± 1.72 kcal/mol), supported by stable hydrogen bond formation with the key oncogenic residues GLU_335 and GLU_336. Comparatively, Vitamin D2 has better compact and structurally stable complex (lowest Rgyr). Crucially, ADMET analysis provided the clinical filter pending experimental confirmation. While Ginkgolide-B showed superior ADME parameters, its major liability as a strong CYP3A4 inhibitor limited its clinical viability. In contrast, Epicatechin potentially offered a favourable balance: strong binding thermodynamics paired with a superior metabolic profile (minimal CYP inhibition). These results strongly suggest that common nutraceuticals, particularly Epicatechin, provide promising, safer, and chemically tractable scaffolds for the development of multi-target small-molecule inhibitors against EBV latency proteins. This work underscores the potential of nutraceuticals in anti-EBV strategies, supporting multi-target approaches for EBV-related diseases.

05 May 2026·Journal of Applied Laboratory Medicine

Comparison of a Reformulated Automated Vitamin D Assay, Its Predecessor, and 2 Contemporary Formulations

Article

Author: Hubbard, Jacqueline A ; Nerenz, Robert D ; Alvarez, Yasel F ; Singh, Ravinder J ; Geno, K Aaron

Abstract:

Background:

Historically, 25-hydroxyvitamin D (25OHD) assays have under- or over-recovered 25-hydroxyvitamin D2 (25OHD2), but assay manufacturers have modified their reagents to address this problem. In this study, we compared the second- and third-generation Roche assays as well as two contemporary offerings from Diasorin and Beckman against liquid chromatography–tandem mass spectrometry (LC-MS/MS).

Methods:

We identified 50 remnant serum samples with 25OHD concentrations from across the analytical range of the second-generation Roche assay. To increase 25OHD2 representation, we identified 25 additional samples from individuals prescribed high-dose vitamin D2 supplements. We tested samples on Roche assays and circulated to laboratories performing Beckman and Diasorin 25OHD assays. We tested samples by LC-MS/MS to obtain concentrations for 25OHD2 and 25-hydroxyvitamin D3.

Results:

Mean overall bias for each assay was 5.1 ng/mL or less against the LC-MS/MS measurement; mean proportional bias was 8.7% to 12.1%. Some individual specimens had much larger bias. 25OHD2 was under-recovered on average, but the bias for the third-generation Roche assay represents a significant improvement over the previous assay, and mean bias for current generation assays was no worse than −3.2 ng/mL. In most cases, clinical classification by automated assay values agreed with clinical classification by LC-MS/MS; where present, disagreements occurred near classification thresholds.

Conclusions:

Automated 25OHD assays continue to improve, and 25OHD2 recovery no longer appears to be a significant concern for the assays evaluated here. All assays evaluated were adequate for clinical classification of vitamin D nutritional status and are suitable for routine use, including in patients prescribed high-dose vitamin D2.

News (Medical) associated with Ergocalciferol

23 May 2026

·www.sciencedaily.com

Scientists warn popular vitamin D supplement may have a “previously unknown” downside

A surprising study suggests vitamin D2 supplements may reduce the body’s levels of vitamin D3 — the more effective form of vitamin D. Researchers found D3 not only boosts vitamin D status more efficiently, but may also play a unique role in helping the immune system fight off viruses and bacteria. The discovery is prompting scientists to rethink whether D3 should become the preferred choice for supplementation.Taking vitamin D2 might lower the body's levels of the more efficient form of vitamin D, vitamin D3, according to new research from the University of Surrey, John Innes Centre and Quadram Institute Bioscience. Many people take vitamin D supplements to support their bone and immune health and meet the UK government recommendation of 10 micrograms (µg) each day, especially during the winter months. There are two forms of vitamin D supplements available: vitamin D2 and vitamin D3. Researchers have found that taking vitamin D2 supplements can lead to a drop in the body's concentration of vitamin D3, which is the form our bodies naturally produce from sunlight and use most effectively to raise overall vitamin D levels. The study, published in Nutrition Reviews, analyzed data from randomized controlled trials and found that vitamin D2 supplementation resulted in a reduction in vitamin D3 levels compared to those not taking a vitamin D2 supplement. In many of the studies, the vitamin D3 levels went lower than in the control group. Emily Brown, PhD Research Fellow and Lead Researcher of the study from the University of Surrey's Nutrition, Exercise, Chronobiology & Sleep Discipline, said: "Vitamin D supplements are important, especially between October and March, when our bodies cannot make vitamin D from sunlight in the UK. However, we discovered that vitamin D2 supplements can actually decrease levels of vitamin D3 in the body, which is a previously unknown effect of taking these supplements. This study suggests that subject to personal considerations, vitamin D3 supplements may be more beneficial for most individuals over vitamin D2." Professor Cathie Martin, Group Leader at the John Innes Centre, said: “This meta-analysis highlights the importance of ensuring plant-based vitamin D3 is accessible in the UK.” This research supports a previous study published in Frontiers in Immunology, led by Professor Colin Smith from the University of Surrey, which suggests that vitamin D2 and D3 do not have identical roles in supporting immune function. Vitamin D3 has a modifying effect on the immune system that could fortify the body against viral and bacterial diseases. Professor Colin Smith said: “We have shown that vitamin D3, but not vitamin D2, appears to stimulate the type I interferon signalling system in the body - a key part of the immune system that provides a first line of defence against bacteria and viruses. Thus, a healthy vitamin D3 status may help prevent viruses and bacteria from gaining a foothold in the body.” Further research into the different functionalities of vitamin D2 and D3 should be a priority in deciding whether vitamin D3 should be the first-line choice of vitamin D supplement, subject to individual requirements. Professor Martin Warren, Chief Scientific Officer at the Quadram Institute, said: "Vitamin D deficiency represents a significant public health concern, especially during the winter months with significant deficiency across the UK population. This collaborative research effort aligns well with the Quadram Institute’s mission to deliver healthier lives through food innovation to enhance the nutrient density of the food we eat. Tackling this with the most effective form of vitamin D supplementation or fortification is of the utmost importance to the health of the nation."

05 Mar 2024

·www.businesswire.com

Northwell Health Researcher Shows Vitamin D Could Improve Insulin-producing Cells in Children With Type 1 Diabetes

MANHASSET, N.Y.--( BUSINESS WIRE )--Approximately 352,000 Americans under the age of 20 have type 1 diabetes, and every year 64,000 Americans more are diagnosed. To help children and young people navigate type 1 diabetes, new research from Cohen Children’s Medical Center and The Feinstein Institutes for Medical Research at Northwell Health shows that taking vitamin D could help improve the function of insulin-producing cells. The study, which was published today in the Journal of the American Medical Association and led by Benjamin Nwosu, MD , chief of endocrinology and director of the diabetes center at Cohen Children’s and researcher with the Feinstein Institutes, looked at a group of young people, ages 10 to 21, who were recently diagnosed with type 1 diabetes. The research showed that by taking high-dose vitamin D, patients saw improvement in the function of insulin-producing cells which could extend the “honeymoon phase” of type 1 diabetes. The honeymoon phase of type 1 diabetes is a crucial time when treatments can make a difference in the long-term outlook of the disease. This research shows that by adding vitamin D, which is inexpensive and easy to obtain, one can make this phase of diabetes last longer. “Type 1 diabetes affects millions of people and treatment options can often be costly,” said Dr. Nwosu, who is the principal author of the paper. “It is exciting to know that vitamin D could protect the beta cells of the pancreas and increase the natural production of good and functional insulin in these patients. This, in turn, prolongs the honeymoon phase of type 1 diabetes and leads to reduced long-term complications of this disease.” When a patient is diagnosed with type 1 diabetes, their pancreas does not make enough insulin, a hormone that moves blood sugar into the cells of the body for energy production. Without insulin, blood sugar cannot get into the cells and instead build up in the bloodstream, which could be damaging to the body and cause the symptoms and complications of diabetes. As part of the 12-month randomized clinical trial, one group took ergocalciferol (a type of vitamin D) as treatment, while the other group took a placebo. Researchers found that taking the vitamin D supplement reduced the proinsulin to C-peptide ratio and delayed the loss of C-peptide more than the placebo did. This means that vitamin D protects the cells that make insulin and ensures that good insulin is made. “Repurposing commonly used supplements such as vitamin D, which is known to be safe and effective for other ailments, presents an opportunity to continue developing other therapies needed to treat type 1 diabetes,” said Charles Schleien, MD, MBA , senior vice president and chair of pediatric services at Northwell Health, and the Philip Lanzkowsky Chair and Professor of Pediatrics at the Zucker School of Medicine at Hofstra/Northwell . “Dr. Nwosu’s research is another step forward to continue our understanding of diabetes and the development of more affordable, yet effective treatment options.” This research builds on Dr. Nwosu’s previous work, which showed that the use of high-dose vitamin D supplementation was safe and effective to improve glucose control and prolong the partial clinical remission phase of type 1 diabetes in children and adolescents. About the Feinstein Institutes The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit http://feinstein.northwell.edu and follow us on LinkedIn .

Clinical Result

05 Mar 2024

·www.biospace.com

Northwell Health Researcher Shows Vitamin D Could Improve Insulin-producing Cells in Children With Type 1 Diabetes

MANHASSET, N.Y.--(BUSINESS WIRE)-- Approximately 352,000 Americans under the age of 20 have type 1 diabetes, and every year 64,000 Americans more are diagnosed. To help children and young people navigate type 1 diabetes, new research from Cohen Children’s Medical Center and The Feinstein Institutes for Medical Research at Northwell Health shows that taking vitamin D could help improve the function of insulin-producing cells. This press release features multimedia. View the full release here: Dr. Benjamin Nwosu’s study shows that vitamin D could be an easier and more affordable option to help adolescents living with type 1 diabetes. (Credit: Feinstein Institutes) The study, which was published today in the Journal of the American Medical Association and led by Benjamin Nwosu, MD, chief of endocrinology and director of the diabetes center at Cohen Children’s and researcher with the Feinstein Institutes, looked at a group of young people, ages 10 to 21, who were recently diagnosed with type 1 diabetes. The research showed that by taking high-dose vitamin D, patients saw improvement in the function of insulin-producing cells which could extend the “honeymoon phase” of type 1 diabetes. The honeymoon phase of type 1 diabetes is a crucial time when treatments can make a difference in the long-term outlook of the disease. This research shows that by adding vitamin D, which is inexpensive and easy to obtain, one can make this phase of diabetes last longer. “Type 1 diabetes affects millions of people and treatment options can often be costly,” said Dr. Nwosu, who is the principal author of the paper. “It is exciting to know that vitamin D could protect the beta cells of the pancreas and increase the natural production of good and functional insulin in these patients. This, in turn, prolongs the honeymoon phase of type 1 diabetes and leads to reduced long-term complications of this disease.” When a patient is diagnosed with type 1 diabetes, their pancreas does not make enough insulin, a hormone that moves blood sugar into the cells of the body for energy production. Without insulin, blood sugar cannot get into the cells and instead build up in the bloodstream, which could be damaging to the body and cause the symptoms and complications of diabetes. As part of the 12-month randomized clinical trial, one group took ergocalciferol (a type of vitamin D) as treatment, while the other group took a placebo. Researchers found that taking the vitamin D supplement reduced the proinsulin to C-peptide ratio and delayed the loss of C-peptide more than the placebo did. This means that vitamin D protects the cells that make insulin and ensures that good insulin is made. “Repurposing commonly used supplements such as vitamin D, which is known to be safe and effective for other ailments, presents an opportunity to continue developing other therapies needed to treat type 1 diabetes,” said Charles Schleien, MD, MBA, senior vice president and chair of pediatric services at Northwell Health, and the Philip Lanzkowsky Chair and Professor of Pediatrics at the Zucker School of Medicine at Hofstra/Northwell. “Dr. Nwosu’s research is another step forward to continue our understanding of diabetes and the development of more affordable, yet effective treatment options.” This research builds on Dr. Nwosu’s previous work, which showed that the use of high-dose vitamin D supplementation was safe and effective to improve glucose control and prolong the partial clinical remission phase of type 1 diabetes in children and adolescents. About the Feinstein Institutes The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes of behavioral science, bioelectronic medicine, cancer, health system science, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine. For more information about how we produce knowledge to cure disease, visit and follow us on LinkedIn. View source version on businesswire.com: Contacts Julianne Mosher Allen 516-880-4824 jmosherallen@northwell.edu Source: Northwell Health Smart Multimedia Gallery Photo Dr. Benjamin Nwosu’s study shows that vitamin D could be an easier and more affordable option to help adolescents living with type 1 diabetes. (Credit: Feinstein Institutes) Logo View this news release and multimedia online at:

Clinical Result

100 Deals associated with Ergocalciferol

External Link

KEGG	Wiki	ATC	Drug Bank
D00187	Ergocalciferol	A11CC01	DB00153

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypocalcemia	China	Sunflower Pharmaceutical Group Co., Ltd.	01 Jan 1982
Hypophosphatemia, Familial	China	Sunflower Pharmaceutical Group Co., Ltd.	01 Jan 1982
Osteomalacia	China	Sunflower Pharmaceutical Group Co., Ltd.	01 Jan 1982
Hypoparathyroidism	United States	Esjay Pharma LLC	11 Jan 1941
Hypophosphatemia	United States	Esjay Pharma LLC	11 Jan 1941
Rickets	United States	Esjay Pharma LLC	11 Jan 1941

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05673980 (Pubmed \| Sci Rep)	Not Applicable	COVID-19 serum 25-hydroxyvitamin D (25(OH)D) \| C-reaction protein (CRP) \| complement component C1q ... View more	228	Vitamin D2	vjihitknzk(pubciiasfv) = axdmomfwfk bqrfqbqauj (vqzzpgyeqc ) View more	Negative	03 Sep 2024
				vitamin D (Non-intervention)	vjihitknzk(pubciiasfv) = hhmhvrkdod bqrfqbqauj (vqzzpgyeqc ) View more
NCT03046927 (PCR, CTgov)	Phase 2/3	Diabetes Mellitus, Type 1	48	Ergocalciferol (Ergocalciferol)	cmlxdylska(efetvblbgu) = sxnwxktixk xjqvvbfwct (tcawzawpjn, 0.28) View more	-	10 Jul 2024
				Placebo (Placebo)	cmlxdylska(efetvblbgu) = czkkufmcap xjqvvbfwct (tcawzawpjn, 0.31) View more
NCT01568255 (CTgov)	Phase 4	Vitamin D Deficiency \| Muscular Diseases	11	Ergocalciferol (Vitamin D Treatment)	cppcfkmnvx = bkjakuewwz mgrkszqyok (xvkptdqvzc, ioolbzzobb - degtotjzid) View more	-	10 Jun 2021
				Placebo (Placebo Group)	cppcfkmnvx = tkitgenbuv mgrkszqyok (xvkptdqvzc, qyeohozcud - zeborwsmez) View more
NCT01173848 (UPGRADE, CTgov)	Phase 3	Chronic Kidney Diseases	19	Ergocalciferol (Vitamin D2)	zgtwcslukz = sggezrlfdk jdeeafmwle (vqkbknwuaa, elosclfzka - lykdtacebb)	-	04 Apr 2017
				cholecalciferol (Vitamin D3)	zgtwcslukz = qbgabslbhd jdeeafmwle (vqkbknwuaa, qgyvyvdmzt - jcgzjdajia)
NCT01426347 (CTgov)	Not Applicable	Vitamin D Deficiency \| Rheumatoid Arthritis	139	Placebo sugar pill+Ergocalciferol (Placebo Group)	inqbyyapbp(qrcnzrfgdh) = uarbshbppz znuovdvxnr (njowumcdyk, 1.5) View more	-	20 Mar 2017
				Ergocalciferol (Ergocalciferol)	inqbyyapbp(qrcnzrfgdh) = lkohreojok znuovdvxnr (njowumcdyk, 1.3) View more
NCT01848236 (Pubmed \| J Clin Endocrinol Metab)	Not Applicable	Vitamin D Deficiency	-	Vitamin D2	qoublajhao(abbkzukebf) = nmdevbmngg vfkhfoqpww (oywssfipmf ) View more	-	01 Aug 2016
				Vitamin D3	qoublajhao(abbkzukebf) = cgjpypcnqt vfkhfoqpww (oywssfipmf ) View more
NCT01633853 (CTgov)	Phase 4	Chronic Kidney Disease-Mineral and Bone Disorder \| Vitamin D Deficiency	204	1,25(OH)2 Vit D3 (1,25(OH)2 Vitamin D3)	olrykxmdzz(tuygkpubpu) = wvqtknzjuo ydzmpnontn (xqfjnyqnjf, 0.14) View more	-	15 Feb 2016
				Vitamin D2 (Vitamin D2 Treatment)	hbuewmgrcg = unjnrsotvs ypiuivmzev (tqhnholpiy, ugziaorxzv - vngognstvs)
NCT00892099 (CTgov)	Not Applicable	Kidney Failure, Chronic \| Infectious Diseases	105	Ergocalciferol (High Dose Ergocalciferol)	wpvwygblrb(zhcyhlvwhw) = knwqcwjrzo imhpaernmp (ixynagudnf, 2.3) View more	-	08 Jun 2015
				Ergocalciferol (Low Dose Ergocalciferol)	wpvwygblrb(zhcyhlvwhw) = lyoeprtlrl imhpaernmp (ixynagudnf, 2.4) View more
NCT01217840 (CTgov)	Not Applicable	Inflammation \| Obesity	40	Ergocalciferol (Vitamin D)	zzlupvbqfv(daexfnxude) = jobyagtmxe yrcaoqaguq (xaunzozopo, 1.4) View more	-	02 Mar 2015
				Placebo (Placebo)	zzlupvbqfv(daexfnxude) = vggsqhitxs yrcaoqaguq (xaunzozopo, 2.6) View more
NCT00742235 (CTgov)	Not Applicable	Vitamin D Deficiency	99	25-OH vitamin D+ergocalciferol	cihkjmixpr(aerrjlmqww) = ombhjxeyhg vukirmchwx (fayfszqtev, 347) View more	-	11 Nov 2013

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis